Form 4: Enliven Therapeutics CEO Samuel Kintz Executes Option and Sells Shares
SEC Form 4 Filing
Enliven Therapeutics CEO Samuel Kintz exercised stock options and sold shares on May 28, 2024, according to a Form 4 filing with the SEC.
Summary
- On May 28, 2024, Samuel Kintz, the President and CEO of Enliven Therapeutics, exercised stock options to acquire 12,000 shares of common stock at a price of $1.12 per share.
- Simultaneously, Kintz sold 6,681 shares at a weighted average price of $22.8643, 5,219 shares at a weighted average price of $23.5715, and 100 shares at $24.34.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2023.
- Following these transactions, Kintz directly owns 5,319 shares and indirectly owns 1,087,525 shares through The Kintz & Egan Trust, 88,531 shares through a trust for his elder son, and 88,531 shares through a trust for his younger son.
- He also directly owns 188,841 derivative securities in the form of stock options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document simply reports insider trading activity under a pre-existing plan. It doesn't inherently indicate positive or negative prospects for the company.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell shares, especially under pre-arranged trading plans like Rule 10b5-1, which allows insiders to trade without being accused of acting on non-public information.
Comparison to Industry Standards
- Insider trading activity is closely monitored in the pharmaceutical industry, similar to companies like Pfizer, Amgen, and Eli Lilly.
- The use of Rule 10b5-1 trading plans is a common practice among executives in publicly traded companies to manage their stock holdings and avoid accusations of insider trading.
- The reported transactions are typical for executives holding stock options and managing their personal finances.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the CEO selling shares, but the existence of a 10b5-1 plan mitigates concerns about insider information being used.
Key Dates
| Date | Description |
|---|---|
| 2019-03-30 | Date of The Kintz & Egan Trust |
| 2021-10-26 | Date of irrevocable trusts for Reporting Person's sons |
| 2023-06-26 | Date the Rule 10b5-1 trading plan was adopted |
| 2024-05-28 | Date of the stock option exercise and share sales |
| 2024-05-30 | Date of signature on the Form 4 |
| 2030-06-16 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.